1. Valeant said it is in talks with potential buyers of its Salix stomach-drug business, which could fetch about $10 billion. The Canadian drugmaker acquired the business for $14.5 billion last year. (Reuters)
2. Pfizer reported 8% growth in its third-quarter revenue in 2016, up from $12.1 billion during the same quarter in 2015 to $13 billion. Key drivers of growth included metastatic breast cancer drug Ibrance and blood thinner Eliquis, as well as the acquisition of pharmaceutical and medical device company Hospira for $1 billion in October.
3. Declining sales of Gilead Sciences’ hep.-C drugs Harvoni and Sovaldi contributed to a 10% decrease in the company’s third-quarter revenue, from $8.3 billion to $7.5 billion.
4. Allergan reported 4.4% growth in revenue, to $3.62 billion, in the third quarter of 2016. The drugmaker said it will expand its share buyback program to $15 billion and set its first quarterly dividend to offset lower-than-expected quarterly revenue. (Reuters)
5. Donald Trump said he would request a “special session” with Congress to repeal and replace Obamacare if he is elected president next week. (Politico)
